DeBakey VAD

DeBakey VAD®

Cardiology A miniaturized ventricular assist device which provides ↑ blood flow in Pts with CHF
References in periodicals archive ?
Washington, Aug 18 (ANI): In a revolutionary surgery, cardiac surgeons at Heidelberg University Hospital for the first time implanted the HeartAssist 5 ventricular assist device, the modern version of the DeBakey VAD in July this year.
The DeBakey VAD was first developed in the 1990s in cooperation with NASA by Professor Michael DeBakey, the renowned American cardiac surgeon at the Baylor College of Medicine in Houston, who died in 2008 at the age of 99.
Jonathan Drummond-Webb, the heart team at Arkansas Children's Hospital performed the world's first successful heart transplant on a child--a 14-year-old Cabot boy--who first had a miniaturized heart pump known as the DeBakey VAD Child, a ventricular assist device.
The supplement changes the patient randomization scheme to a 2:1 ratio of MicroMed DeBakey VAD implants to Thoratec HeartMate XVE implants.
The company reports the MicroMed DeBakey VAD is smaller than any other LVAD currently on the market and has been implanted in 85 patients to date.
With approximately 2,000 donor hearts suitable for transplantation becoming available each year in the United States or 4,000 worldwide, MicroMed believes that the DeBakey VAD represents an important therapeutic option for this population.
The proceeds of the transaction are expected to support continued clinical studies and research associated with the Company's DeBakey VAD(R), expansion of sales and marketing activities in international markets where the DeBakey VAD has received CE Mark approval, and for general corporate purposes.
MicroMed has joined with eight leading centers across Europe to evaluate the latest refinements to the DeBakey VAD technology.
The patient, who was 78 at the time of the procedure, received the DeBakey VAD at California Pacific Medical Center (CPMC) in San Francisco in early November, 2004 by Dr.
With less than 1% of donor organs available for heart transplantation, MicroMed believes that the DeBakey VAD is a key alternative for this population.
The merger and concurrent financing will enable us to move forward as a public company, giving us greater access to the capital markets and more exposure for our DeBakey VAD technology," said Travis E.
The DeBakey VAD was implanted as a bridge to heart transplantation under MicroMed's clinical trial for that indication.